文献速递急性肾损伤慢性肾脏病

肠源性高草酸尿症临床试验终点考量

End Point Considerations for Clinical Trials in Enteric Hyperoxaluria.
PubMed 文献 · Clin J Am Soc Nephrol · 2023-06-21

肠源性高草酸尿症因胃肠道草酸吸收增加导致尿草酸升高,可致肾结石、肾钙质沉着,并与CKD和肾衰竭相关。目前美国FDA未批准任何疗法,终点尚不明确。肾脏健康倡议多学科工作组综述潜在临床试验终点,因数据缺口未能给出确定性推荐。

要点

  • 潜在临床结局为有症状的肾结石事件。
  • 潜在替代终点包括不可逆肾功能丧失、影像学无症状结石生长/新发、尿草酸及草酸钙过饱和度、血浆草酸。
  • 因数据缺口,工作组未能提供确定性推荐。

核心结论

  • 肾脏健康倡议工作组因数据缺口无法为肠源性高草酸尿症临床试验终点提供确定性推荐。
  • 目前美国FDA未批准任何针对肠源性高草酸尿症的疗法。

研究设计与样本

  • 肾脏健康倡议召集的多学科工作组对肠源性高草酸尿症临床试验潜在终点的证据进行综述。

主要发现

  • 有症状的肾结石事件可作为潜在临床结局。
  • 不可逆肾功能丧失可作为进展至肾衰竭的替代终点。
  • 影像学观察到的无症状结石生长或新发结石可作为有症状肾结石事件的替代终点。
  • 尿草酸和尿草酸钙过饱和度可作为有症状肾结石事件发生的替代终点。
  • 血浆草酸可作为全身性草酸沉着症临床表现发生的替代终点。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 因数据缺口,工作组无法提供确定性推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Enteric hyperoxaluria is a medical condition characterized by elevated urinary oxalate excretion due to increased gastrointestinal oxalate absorption. Causative features include fat malabsorption and/or increased intestinal permeability to oxalate. Enteric hyperoxaluria has long been known to cause nephrolithiasis and nephrocalcinosis, and, more recently, an association with CKD and kidney failure has been shown. Currently, there are no US Food and Drug Administration-approved therapies for enteric hyperoxaluria, and it is unclear what end points should be used to evaluate the efficacy of new drugs and biologics for this condition. This study represents work of a multidisciplinary group convened by the Kidney Health Initiative to review the evidence supporting potential end points for clinical trials in enteric hyperoxaluria. A potential clinical outcome is symptomatic kidney stone events. Potential surrogate end points include ( 1 ) an irreversible loss of kidney function as a surrogate for progression to kidney failure, ( 2 ) asymptomatic kidney stone growth/new stone formation observed on imaging as a surrogate for symptomatic kidney stone events, ( 3 ) urinary oxalate and urinary calcium oxalate supersaturation as surrogates for the development of symptomatic kidney stone events, and ( 4) plasma oxalate as a surrogate for the development of the clinical manifestations of systemic oxalosis. Unfortunately, because of gaps in the data, this Kidney Health Initiative workgroup was unable to provide definitive recommendations. Work is underway to obtain robust information that can be used to inform trial design and medical product development in this space.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Langman CB, Assimos D, Blank M, et al. End Point Considerations for Clinical Trials in Enteric Hyperoxaluria. Clin J Am Soc Nephrol. 2023. PMID: 37342976. doi:10.2215/CJN.0000000000000234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。